$ANNX

Satter Muneer A purchased $3.3M of ANNX (indirect holdings)

Satter Muneer A purchased 613,497 indirectly-held shares of Annexon, Inc. (ANNX) at $5.41 ($3.32M total) on 2026-05-28.

Original reporting
SEC EDGAR · Satter Muneer A
Published May 29, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANNX
Bullish
medium confidence
Mentioned
$ANNX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANNXBullishLow
01

Why it matters

The disclosed open-market buy is a sentiment input for ANN X, but it does not provide new company fundamentals (no trial results, guidance, or deal terms).

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; traders may still discount the signal if the broader newsflow (clinical/financing) is unchanged.

Relevance 7/10Novelty 6/10Timing: Filed May 29, transaction dated May 28 (post-transaction disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Annexon, Inc. (ANNX).

Company-level read

Ticker impact

$ANNXBullishMedium confidence
Context

Annexon director Satter Muneer A bought 613,497 shares in an open-market transaction worth about $3.32M, signaling insider accumulation.

Expected impact

Mild positive bias; likely limited/short-lived impact unless followed by additional news.

Evidence & confidence

Form 4 shows a sizable director purchase, but no new operational/clinical/regulatory development is disclosed in the filing.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide trigger.

None indicated.

None indicated.

Counterpoint

Insider purchases on Form 4 can reflect diversification or planned liquidity needs rather than a strong forward-looking view.

Key entities

  • Annexon, Inc.

    Subject of the Form 4 insider purchase; director bought 613,497 shares at $5.41 on May 28.

  • Satter Muneer A

    Director who executed the open-market purchase; holdings increased to 10,342,134 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

$ANNXMedAI 8/10

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.

$ANNXMed

Annexon Q2 Earnings Call Highlights

Annexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.

$ANNXMed

Annexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon

Annexon Biosciences (ANNX) reported Q2 2026 results and clinical updates. It said Phase 3 FORWARD tanruprubart in Guillain-Barre has treated the first 10 U.S. and European patients and expects a Q4 2026 BLA filing. For vonaprument in geographic atrophy, ARCHER II remains on track with Month 15 data in Q4 2026 and final completion in Q3 2027. Q2 R&D was $46.6M, net loss $55.3M. Cash was $209.2M. A $200M credit facility was arranged with $50M drawn.

$SMCIHighAI 8/10

Super Micro jumps premarket on outlook boost, H&R Block surges

U.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.

$ANNXMedAI 8/10

Annexon Biosciences: Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.